Shield Therapeutics plc (SHIEF)

Market Cap	24.41M
Revenue (ttm)	32.18M
Net Income (ttm)	-27.18M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,020
Average Volume	151,816
Open	0.0340
Previous Close	0.0345
Day's Range	0.0340 - 0.0340
52-Week Range	0.0135 - 0.0614
Beta	1.44
RSI	42.77
Earnings Date	Apr 25, 2025

About Shield Therapeutics

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 73
• Stock Exchange: OTCMKTS
• Ticker Symbol: SHIEF

Financial Performance

In 2023, Shield Therapeutics's revenue was $13.09 million, an increase of 137.95% compared to the previous year's $5.50 million. Losses were -$33.29 million, -33.13% less than in 2022.